NCT05596747View on ClinicalTrials.gov

A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

October 10, 2023

Study Completion Date

October 10, 2023

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

LY3209590

Administered SC.

DRUG

Insulin Glargine

Administered SC.

Trial Locations (1)

300052

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY